Changchun Hi-Tech announced that according to the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue” issued by the National Health Insurance Administration and the Ministry of Human Resources and Social Affairs, Jin Beixin, independently developed by the company's holding subsidiary Changchun Jinsai Pharmaceutical Co., Ltd., was newly included in the national medical insurance catalogue. The medical insurance payment standard is limited to those with contraindications, intolerance, or lack of curative effect on non-steroidal anti-inflammatory drugs and/or colchicine, as well as those with acute attacks of gout arthritis in adults who are not suitable for repeated use of steroids. Period 2027 January 1 to 2028 December 31st The new version of the National Health Insurance Catalogue will be officially implemented on January 1, 2027. Currently, the impact on the company's operating performance cannot be estimated.

Zhitongcaijing · 1d ago
Changchun Hi-Tech announced that according to the “National Basic Medical Insurance, Maternity Insurance and Work Injury Insurance Drug Catalogue” issued by the National Health Insurance Administration and the Ministry of Human Resources and Social Affairs, Jin Beixin, independently developed by the company's holding subsidiary Changchun Jinsai Pharmaceutical Co., Ltd., was newly included in the national medical insurance catalogue. The medical insurance payment standard is limited to those with contraindications, intolerance, or lack of curative effect on non-steroidal anti-inflammatory drugs and/or colchicine, as well as those with acute attacks of gout arthritis in adults who are not suitable for repeated use of steroids. Period 2027 January 1 to 2028 December 31st The new version of the National Health Insurance Catalogue will be officially implemented on January 1, 2027. Currently, the impact on the company's operating performance cannot be estimated.